Amgen Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone, from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce Amgen, and Chairman and CEO, Bob Bradway.
Please note that following the presentation, we will move right into a Q&A session where you can send in questions via the conference portal, and I'll do my best to work them into the conversation.
So with that, Bob, thanks, as always, for joining us today, and let me turn things over to you for an update.
Okay. Cory, thanks very much. Happy New Year to you and thanks for having us again this year. We're excited to be here. As we look at 2022 and beyond, we think things are setting up pretty well for us to be able to deliver attractive long-term growth for our shareholders. And so I'd like to talk a little bit about that in our time together this morning.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |